Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Rigosertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 4/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 0.81 |
| ▸ | NQO2 | P16083 | 1/20 | 0.81 |
| ▸ | FECH | P22830 | 1/20 | 0.81 |
| ▸ | CLK3 | P49761 | 1/20 | 0.81 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.78 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.78 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.78 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.78 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.78 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.78 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.78 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.78 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.78 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.78 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.78 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rigosertib SCHEMBL4726480 | 1.00 | PLK1 (1.00) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL29360545 | 1.00 | PLK1 (1.00) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL29397572 | 0.90 | PLK1 (1.00) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL498623 | 0.90 | PLK1 (1.00) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL498448 | 0.90 | PLK1 (0.84) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL498447 | 0.90 | PLK1 (0.84) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL498624 | 0.90 | PLK1 (1.00) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL498728 | 0.89 | PLK1 (0.98) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL498730 | 0.89 | PLK1 (0.98) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL15835693 | 0.85 | PLK1 (0.77) | PLK1METNQO2FECHCLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 997 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005814-A | Drug-loaded polymer micelle, gel drug system, preparation method and application | 苏州大学 | 2026-05-12 | — | — | CN | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-20260092327-A1 | METHODS OF MONITORING MUTATIONS IN TREATMENT OF COLORECTAL CANCER | CARDIFF ONCOLOGY INC (US) | 2026-04-02 | — | — | US | claimed |
| US-20260076970-A1 | CANCER TREATMENT USING MTDP INHIBITORS AND PLK1 INHIBITORS | CARDIFF ONCOLOGY INC (US) | 2026-03-19 | — | — | US | claimed |
| WO-2025240673-A1 | CANCER TREATMENT USING AKT INHIBITORS AND PLK1 INHIBITORS | CARDIFF ONCOLOGY, INC. (US) | 2025-11-20 | — | — | WO | claimed |
| US-20250339680-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2025-11-06 | — | — | US | claimed |
| EP-4618962-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER | Onconova Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| EP-4583983-A1 | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER | Cardiff Oncology, Inc. (US) | 2025-07-16 | — | — | EP | claimed |
| US-20220127682-A1 | SELECTION AND TREATMENT OF CANCER WITH COMBINATION THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-04-28 | — | — | US | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| WO-2022055721-A1 | SELECTION AND TREATMENT OF CANCER WITH COMBINATION THERAPIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-03-17 | — | — | WO | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| EP-3946313-A1 | PLK1 INHIBITORS AND PSA LEVELS IN PROSTATE CANCER | Cardiff Oncology, Inc. (US) | 2022-02-09 | — | — | EP | claimed |
| US-8664272-B2 | Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia | Temple University—Of the Commonwealth System of Higher Education (US) | 2014-03-04 | — | — | US | claimed |
| US-20100305059-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-12-02 | — | — | US | claimed |
| US-7598232-B2 | Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-10-06 | — | — | US | claimed |
| WO-2008027049-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-03-06 | — | — | WO | claimed |
| WO-2006104668-A2 | COMPOSITION AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-10-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076970-A1 | CANCER TREATMENT USING MTDP INHIBITORS AND PLK1 INHIBITORS | PLK1, PLK4, PLK2 | PLK1 1/4885MET 269/4885NQO2 3366/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | PLK1 68/4885MET 724/4885NQO2 3408/4885 |
| US-20220127682-A1 | SELECTION AND TREATMENT OF CANCER WITH COMBINATION THERAPIES | PLK4, PLK2, BUB1B | PLK1 5/4885MET 1794/4885NQO2 2649/4885 |
| US-20100305059-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | DNMT3A, TET2, MCL1 | PLK1 1774/4885MET 185/4885NQO2 1285/4885 |
| US-20260092327-A1 | METHODS OF MONITORING MUTATIONS IN TREATMENT OF COLORECTAL CANCER | KRAS, HRAS, NRAS | PLK1 25/4885MET 136/4885NQO2 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.